News
Windward Bio catches $175m from its IPO

Windward Bio catches $175m from its IPO

Swiss biotech Windward Bio has raised $175m in its Nasdaq IPO as it prepares to take on some heavyweight rivals with its long-acting TSLP inhibitor.

News
FTC said to be planning legal action against PBMs

FTC said to be planning legal action against PBMs

The Federal Trade Commission in the US is planning to sue the owners of the three largest pharmacy benefits managers (PBMs) for anti-competitive behaviour, on the heels of its damning repor

News
atopic dermatitis

NICE backs monthly eczema drug from Almirall

NHS England has been cleared to allow prescribing of Almirall’s Ebglyss for some people with atopic dermatitis, giving them the option of a therapy that only needs to be injected once a mon

Sales & Marketing

Digital

Market Access

Newsletters and Deep Dive
digital magazine

Oncology

Patients

R&D

News
Windward Bio catches $175m from its IPO

Windward Bio catches $175m from its IPO

Swiss biotech Windward Bio has raised $175m in its Nasdaq IPO as it prepares to take on some heavyweight rivals with its long-acting TSLP inhibitor.

Partner Content

Partner Content
LEAP HR: Life Sciences Europe
Partner Content

LEAP HR: Life Sciences Europe

Europe’s Only Industry-Specific Meeting Advancing HR Excellence in Life Sciences